<DOC>
	<DOCNO>NCT00303472</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability romiplostim thrombocytopenic patient low Intermediate-1 risk MDS . In addition , study evaluate platelet response romiplostim .</brief_summary>
	<brief_title>Determination Safe Dose Romiplostim ( AMG 531 ) Patients With Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Diagnosis MDS use World Health Organization classification Low Intermediate1 risk MDS use International Prognostic Scoring System ( IPSS ) The mean two platelet count take screening period must ≤ 50 x 10^9/L , individual count &gt; 55 x 10^9/L ( The mean platelet count 5 subject enrol maximum tolerate dose ( MTD ) must ≤ 20 x 10^9/L ) . Standard care platelet assessment take prior Informed Consent may use 1 2 count take within 3 week prior study day 1 . Must ≥ 18 year age time obtain informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 02 time screen Adequate Liver Function , evidence serum bilirubin ≤ 1.5 time laboratory normal range ( except patient confirm diagnosis Gilbert 's Disease ) , alanine aminotransferase ( ALT ) ≤ 3 time laboratory normal range , aspartate aminotransferase ( AST ) ≤ 3 time laboratory normal range A serum creatinine concentration ≤ 2 mg/dL ( ≤ 176.6 µmol/L ) Before studyspecific procedure , appropriate write informed consent must obtain ( see Section 12.1 ) Currently receive treatment MDS transfusion erythropoietic growth factor . If granulocyte growth factor currently receive , use study day 1 Clinically significant bleeding within 2 week prior screen ( eg , gastrointestinal ( GI ) bleeds , intracranial hemorrhage ) Prior malignancy ( controlled prostate cancer , situ cervical cancer basal cell cancer skin ) unless treat curative intent without evidence disease ≥ 3 year screen Prior history bone marrow transplantation Persistent peripheral blood monocytosis ( ≥ 3 month absolute monocyte count &gt; 1,000/µL ) Unstable angina , congestive heart failure ( New York Heart Association [ NYHA ] &gt; class II ) , uncontrolled hypertension ( diastolic &gt; 100 mmHg ) , uncontrolled cardiac arrhythmia , recent ( within 1 year ) myocardial infarction Received AntiThymocyte Globuline ( ATG ) within 6 month screen Received hypomethylating agent , immunomodulating agent , histone deacetylase inhibitor , cyclosporine mycophenolate within 6 week screen Received interleukin ( IL ) 11 ( oprelvekin ) within 4 week screen Concurrent use granulocyte growth factor ( i.e . granulocytecolony stimulate factor [ GCSF ; Neupogen , Granocyte ] , pegfilgrastim [ Neulasta ] , granulocyte macrophagecolony stimulate factor [ GMCSF ; Leukine , Prokine , Sargramostim ] ) Have ever previously receive recombinant thrombopoietin ( rTPO ) , pegylated recombinant human megakaryocyte growth development factor ( PEGrHuMGDF ) , eltrombopag , romiplostim Less 4 week since receipt therapeutic drug device Food Drug Administration ( FDA ) approve indication Other investigational procedure exclude History arterial thrombosis ( eg , stroke transient ischemic attack ) past year History venous thrombosis currently require anticoagulation therapy Untreated B12 folate deficiency Subject evidently pregnant ( eg , positive human chorionic gonadotropin [ HCG ] test ) breast feed Subject use adequate contraceptive precaution Subject know hypersensitivity recombinant E coliderived product Subject previously enrol study Subject available followup assessment Subject kind disorder compromise ability subject give write informed consent and/or comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>Refractory Cytopenias</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>